News
Click here for news in Danish.
August 05, 2020 | Press Releases
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert® in the U.S. Supported by a U.S. Commercial Team December 09, 2019 | Press Releases
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakNovember 14, 2019 | Press Releases
Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine November 11, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox VaccineNovember 06, 2019 | Press Releases
Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature CommunicationsOctober 31, 2019 | Press Releases
Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the CongoOctober 03, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 2 Trial in Chordoma PatientsJune 25, 2019 | Press Releases
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsJanuary 25, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 TrialJanuary 24, 2019 | Press Releases
Bavarian Nordic Advances Development of Equine Encephalitis Virus VaccineSeptember 19, 2018 | Press Releases
Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox CasesAugust 21, 2018 | Press Releases
Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise May 16, 2018 | Press Releases
Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting September 14, 2017 | Press Releases
Bavarian Nordic to Host Capital Markets Day in New York CitySeptember 11, 2017 | Press Releases
Principal Investigator Dr. James Gulley to Provide Presentation Entitled “Therapeutic Vaccines in Prostate Cancer” at the ESMO 2017 Congress April 19, 2017 | Press Releases
Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate CancerDecember 29, 2016 | Press Releases
Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung CancerDecember 14, 2016 | Press Releases
Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine October 10, 2016 | Press Releases
Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC and Ipilimumab in Patients with Localized Prostate CancerSeptember 29, 2016 | Press Releases
Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV SymposiumSeptember 28, 2016 | Press Releases
Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical OfficerSeptember 12, 2016 | Press Releases
Bavarian Nordic Announces that Janssen has completed a Submission for Emergency Use Assessment and Listing for its Ebola Vaccine Regimen to the World Health OrganizationApril 19, 2016 | Press Releases
Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMAFebruary 04, 2016 | Press Releases
Bavarian Nordic Enters Research Collaboration to Develop MRSA VaccineOctober 28, 2015 | Press Releases
Bavarian Nordic Applauds Recommendations Outlined by U.S. Blue Ribbon Study Panel on Biodefense